Incidence of moxifloxacin resistance in clinical Mycobacterium tuberculosis isolates in Houston, Texas

Journal of Clinical Microbiology

Volumn 49, Issue 8, 2011, Pages 2942-2945

  El Sahly, Hana M ^a   Teeter, Larry D ^b   Jost Jr , Kenneth C ^c   Dunbar, Denise ^c   Lew, Justin ^b   Graviss, Edward A ^b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b HOUSTON METHODIST RESEARCH INSTITUTE   (United States)

^c TEXAS DEPARTMENT OF STATE HEALTH SERVICES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MOXIFLOXACIN; OFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ADULT; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GENE; BACTERIAL STRAIN; BACTERIUM ISOLATE; CONTROLLED STUDY; FEMALE; GENE SEQUENCE; GENOTYPE; GYRA GENE; GYRB GENE; HUMAN; INCIDENCE; MALE; MICROBIOLOGICAL EXAMINATION; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RV2686C GENE; RV2687C GENE; RV2688C GENE; SPOLIGOTYPING; UNITED STATES;

ADULT; ANTITUBERCULAR AGENTS; AZA COMPOUNDS; BACTERIAL PROTEINS; DNA, BACTERIAL; DRUG RESISTANCE, BACTERIAL; FEMALE; HUMANS; INFANT; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MOLECULAR SEQUENCE DATA; MOLECULAR TYPING; MYCOBACTERIUM TUBERCULOSIS; OFLOXACIN; PREVALENCE; QUINOLINES; SEQUENCE ANALYSIS, DNA; TEXAS;

MYCOBACTERIUM TUBERCULOSIS;

EID: 79960953037     PISSN: 00951137     EISSN: 1098660X     Source Type: Journal    
DOI: 10.1128/JCM.00231-11     Document Type: Article

References (36)

1. Aubry, A., et al. 2006. Novel gyrase mutations in quinolone-resistant and -hypersusceptible clinical isolates of Mycobacterium tuberculosis: functional analysis of mutant enzymes. Antimicrob. Agents Chemother. 50:104-112.
2. Chang, K. C., et al. 2010. Newer fluoroquinolones for treating respiratory infection: do they mask tuberculosis? Eur. Respir. J. 35:606-613.
3. CLSI/NCCLS. 2003. Susceptibility testing of mycobacteria, nocardiae, and other aerobic actinomycetes; approved standards. Vol. 23, no. 18. M24-A. NCCLS, Wayne, PA.
4. Conde, M. B., et al. 2009. Moxifloxacin versus ethambutol in the initial treatment of tuberculosis: a double-blind, randomised, controlled phase II trial. Lancet 373:1183-1189.
5. Dam, T., M. Isa, and M. Bose. 2005. Drug-sensitivity profile of clinical Mycobacterium tuberculosis isolates - a retrospective study from a chest-disease institute in India. J. Med. Microbiol. 54:269-271.
6. Devasia, R. A., et al. 2009. Fluoroquinolone resistance in Mycobacterium tuberculosis: the effect of duration and timing of fluoroquinolone exposure. Am. J. Respir. Crit. Care Med. 180:365-370.
7. Devaux, I., K. Kremer, H. Heersma, and D. Van Soolingen. 2009. Clusters of multidrug-resistant Mycobacterium tuberculosis cases, Europe. Emerg. Infect. Dis. 15:1052-1060.
8. Drobniewski, F., et al. 2005. Drug-resistant tuberculosis, clinical virulence, and the dominance of the Beijing strain family in Russia. JAMA 293:2726-2731. (Pubitemid 40965084)
9. Duong, D. A., et al. 2009. Beijing genotype of Mycobacterium tuberculosis is significantly associated with high-level fluoroquinolone resistance in Vietnam. Antimicrob. Agents Chemother. 53:4835-4839.
10. El Sahly, H. M., L. D. Teeter, R. R. Pawlak, J. M. Musser, and E. A. Graviss. 2006. Drug-resistant tuberculosis: a disease of target populations in Houston, Texas. J. Infect. 53:5-11. (Pubitemid 43960451)
11. Fung-Tomc, J., et al. 2000. In vitro antibacterial spectrum of a new broad-spectrum 8-methoxy fluoroquinolone, gatifloxacin. J. Antimicrob. Chemother. 45:437-446.
12. Ghebremichael, S., et al. 2010. Drug resistant Mycobacterium tuberculosis of the Beijing genotype does not spread in Sweden. PLoS One 5:e10893.
13. Ginsburg, A. S., J. H. Grosset, and W. R. Bishai. 2003. Fluoroquinolones, tuberculosis, and resistance. Lancet Infect. Dis. 3:432-442.
14. Grimaldo, E. R., et al. 2001. Increased resistance to ciprofloxacin and ofloxacin in multidrug-resistant Mycobacterium tuberculosis isolates from patients seen at a tertiary hospital in the Philippines. Int. J. Tuberc. Lung Dis. 5:546-550.
15. Huang, T. S., et al. 2005. Trends in fluoroquinolone resistance of Mycobacterium tuberculosis complex in a Taiwanese medical centre: 1995-2003. J. Antimicrob. Chemother. 56:1058-1062.
16. Jacobs, M. R. 1999. Activity of quinolones against mycobacteria. Drugs 58(Suppl. 2):19-22. (Pubitemid 29500080)
17. Kam, K. M., et al. 2006. Stepwise decrease in moxifloxacin susceptibility amongst clinical isolates of multidrug-resistant Mycobacterium tuberculosis: correlation with ofloxacin susceptibility. Microb. Drug Resist. 12:7-11.
18. Kamerbeek, J., et al. 1997. Simultaneous detection and strain differentiation of Mycobacterium tuberculosis for diagnosis and epidemiology. J. Clin. Microbiol. 35:907-914.
19. Klemens, S. P., C. A. Sharpe, M. C. Rogge, and M. H. Cynamon. 1994. Activity of levofloxacin in a murine model of tuberculosis. Antimicrob. Agents Chemother. 38:1476-1479.
20. Kobaidze, K., A. Salakaia, and H. M. Blumberg. 2009. Over the counter availability of antituberculosis drugs in Tbilisi, Georgia in the setting of a high prevalence of MDR-TB. Interdiscip. Perspect. Infect. Dis. 2009:513609.
21. Long, R., et al. 2009. Empirical treatment of community-acquired pneumonia and the development of fluoroquinolone-resistant tuberculosis. Clin. Infect. Dis. 48:1354-1360.
22. Lubasch, A., I. Keller, K. Borner, P. Koeppe, and H. Lode. 2000. Comparative pharmacokinetics of ciprofloxacin, gatifloxacin, grepafloxacin, levofloxacin, trovafloxacin, and moxifloxacin after single oral administration in healthy volunteers. Antimicrob. Agents Chemother. 44:2600-2603.
23. Mitnick, C. D., et al. 2008. Comprehensive treatment of extensively drug-resistant tuberculosis. N. Engl. J. Med. 359:563-574.
24. Mokrousov, I., et al. 2008. Molecular characterization of ofloxacin-resistant Mycobacterium tuberculosis strains from Russia. Antimicrob. Agents Chemother. 52:2937-2939.
25. Pasca, M. R., et al. 2004. Rv2686c-Rv2687c-Rv2688c, an ABC fluoroquinolone efflux pump in Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 48:3175-3178.
26. Ritacco, V., et al. 2008. Mycobacterium tuberculosis strains of the Beijing genotype are rarely observed in tuberculosis patients in South America. Mem. Inst. Oswaldo Cruz 103:489-492.
27. Rodriguez, J. C., M. Ruiz, M. López, and G. Royo. 2002. In vitro activity of moxifloxacin, levofloxacin, gatifloxacin and linezolid against Mycobacterium tuberculosis. Int. J. Antimicrob. Agents 20:464-467.
28. Ruiz-Serrano, M. J., et al. 2000. In vitro activities of six fluoroquinolones against 250 clinical isolates of Mycobacterium tuberculosis susceptible or resistant to first-line antituberculosis drugs. Antimicrob. Agents Chemother. 44:2567-2568.
29. Schentag, J. J., K. K. Gilliland, and J. A. Paladino. 2001. What have we learned from pharmacokinetic and pharmacodynamic theories? Clin. Infect. Dis. 32(Suppl. 1):S39-S46.
30. Sulochana, S., F. Rahman, and C. N. Paramasivan. 2005. In vitro activity of fluoroquinolones against Mycobacterium tuberculosis. J. Chemother. 17:169-173.
31. Sun, Z., et al. 2008. Comparison of gyrA gene mutations between laboratory-selected ofloxacin-resistant Mycobacterium tuberculosis strains and clinical isolates. Int. J. Antimicrob. Agents 31:115-121.
32. Supply, P., et al. 2001. Automated high-throughput genotyping for study of global epidemiology of Mycobacterium tuberculosis based on mycobacterial interspersed repetitive units. J. Clin. Microbiol. 39:3563-3571.
33. Tan, C. K., et al. 2009. Comparative in vitro activities of the new quinolone nemonoxacin (TG-873870), gemifloxacin and other quinolones against clinical isolates of Mycobacterium tuberculosis. J. Antimicrob. Chemother. 64:428-429.
34. Veziris, N., C. Truffot-Pernot, A. Aubry, V. Jarlier, and N. Lounis. 2003. Fluoroquinolone-containing third-line regimen against Mycobacterium tuberculosis in vivo. Antimicrob. Agents Chemother. 47:3117-3122.
35. Von Groll, A., et al. 2009. Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB. Antimicrob. Agents Chemother. 53:4498-4500.
36. Wright, D. H., G. H. Brown, M. L. Peterson, and J. C. Rotschafer. 2000. Application of fluoroquinolone pharmacodynamics. J. Antimicrob. Chemother. 46:669-683.